Acurx Pharmaceuticals posts presentation on ibezapolstat microbiome restoration potential in recurrent C. difficile infection

• Acurx published research comparing ibezapolstat with fidaxomicin, vancomycin in patients with multiply recurrent C. difficile infection.
• Study found beneficial microbes remained present in these patients’ microbiomes, though at lower proportions.
• Reported higher vancomycin-resistant Enterococcus levels; ibezapolstat exposure in CDI patients was described as sufficient to kill VRE.
• Lab models showed VRE overgrowth with vancomycin; ibezapolstat, fidaxomicin outperformed in biofilms.
• Ibezapolstat was significantly more effective at C. difficile killing than vancomycin, fidaxomicin in biofilm experiments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief on July 13, 2026, and is solely responsible for the information contained therein.